Bioclinical markers in breast cancer: updates and perspectives.

Molecular studies have definitely changed our knowledge of the biology of cancers, and breast cancer's tremendous social impact has stimulated a large mass of research. Classic markers have opened a road, but their usefulness appears limited to prognosis or follow up, while several new markers, both genetic and molecular, are assuming different, yet still controversial, importance: they may play a major role in the surveillance of subjects at risk, in detecting primary or recurrent cancers, and in predicting the need of adjuvant therapy, or the response to therapy. .

[1]  Carlos Caldas,et al.  Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer , 2008, BMC Cancer.

[2]  Q. Chu,et al.  Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC) , 2008, Breast Cancer Research and Treatment.

[3]  Arndt Hartmann,et al.  Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients , 2008, Breast Cancer Research.

[4]  J. Forbes,et al.  Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  C. Schubert,et al.  Cytokine Comparisons Between Women With Breast Cancer and Women With a Negative Breast Biopsy , 2008, Nursing research.

[6]  S. Paik,et al.  Development of the 21-gene assay and its application in clinical practice and clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Marta Cuadros,et al.  Systematic Review of HER2 Breast Cancer Testing , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[8]  Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial , 2007 .

[9]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[10]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  O. Olopade,et al.  Advances in Breast Cancer: Pathways to Personalized Medicine , 2008, Clinical Cancer Research.

[12]  A. Scorilas,et al.  Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. , 2008, The oncologist.

[13]  L. Carey,et al.  What is triple-negative breast cancer? , 2008, European journal of cancer.

[14]  N. Brünner,et al.  TIMP-1 as a tumor marker in breast cancer – An update , 2008, Acta oncologica.

[15]  J. Kurebayashi [Biomarkers in breast cancer]. , 2004, Gan to kagaku ryoho. Cancer & chemotherapy.

[16]  L. Demers,et al.  Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Murphy,et al.  Estrogen receptor alpha negative breast cancer patients: Estrogen receptor beta as a therapeutic target , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[18]  Peter Kraft,et al.  Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics , 2008, PLoS genetics.

[19]  F. Schmitt,et al.  EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy , 2008, Expert review of molecular diagnostics.

[20]  J. Baselga,et al.  Targeted therapies in breast cancer: where are we now? , 2008, European journal of cancer.

[21]  M. Sormani,et al.  HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. , 2008, Journal of the National Cancer Institute.

[22]  Mai Brooks,et al.  Breast cancer screening and biomarkers. , 2009, Methods in molecular biology.

[23]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[24]  N. Sneige,et al.  Triple Negative Breast Carcinoma and the Basal Phenotype: From Expression Profiling to Clinical Practice , 2007, Advances in anatomic pathology.

[25]  R. Neve,et al.  Unraveling the biologic and clinical complexities of HER2. , 2008, Clinical breast cancer.

[26]  S. Stein,et al.  Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer , 2008, Nature Clinical Practice Oncology.

[27]  P. Birembaut,et al.  Prognostic value of a proliferation index including MIB1 and argyrophilic nucleolar organizer regions proteins in node-negative breast cancer. , 2008, American journal of obstetrics and gynecology.

[28]  J. Benítez,et al.  The Molecular Pathology of Hereditary Breast Cancer , 2008, Pathobiology.

[29]  P. Drew,et al.  Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). , 2006, Oncology reports.

[30]  M. Wicha Cancer stem cell heterogeneity in hereditary breast cancer , 2008, Breast Cancer Research.

[31]  M. Georgescu NHERF1: molecular brake on the PI3K pathway in breast cancer , 2008, Breast Cancer Research.

[32]  P. Muti,et al.  Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. , 2006, Biochimica et biophysica acta.

[33]  F. Puglisi,et al.  Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[35]  B. Riche,et al.  Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator. , 2008, Clinical breast cancer.

[36]  S. Koscielny Critical review of microarray-based prognostic tests and trials in breast cancer , 2008, Current opinion in obstetrics & gynecology.

[37]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[38]  C. Boetes,et al.  Breast MRI: guidelines from the European Society of Breast Imaging , 2008, European Radiology.

[39]  Marc Tischkowitz,et al.  Use of immunohistochemical markers can refine prognosis in triple negative breast cancer , 2007, BMC Cancer.

[40]  R. Nahta,et al.  Her2 cross talk and therapeutic resistance in breast cancer. , 2008, Frontiers in bioscience : a journal and virtual library.

[41]  Sami Kilpinen,et al.  Role of ErbB4 in Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[42]  F. Esteva,et al.  Her2-positive breast cancer: herceptin and beyond. , 2008, European journal of cancer.

[43]  J. Bergh,et al.  Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.

[44]  B. Henderson,et al.  Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort , 2009, BMC Cancer.

[45]  J. Foekens,et al.  Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D. Stern ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[48]  J. Khatcheressian,et al.  Breast cancer follow-up in the adjuvant setting , 2008, Current oncology reports.

[49]  C. Singer,et al.  Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. , 2008, Biochimica et biophysica acta.

[50]  I. Ellis,et al.  Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. , 2005, Endocrine-related cancer.

[51]  F. Monti,et al.  p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  J. Foekens,et al.  Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  H. Gómez,et al.  Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  J. Bartlett,et al.  Predictive markers in breast cancer – the future , 2007, Histopathology.

[55]  Alice S Whittemore,et al.  Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. , 2007, JAMA.

[56]  Lajos Pusztai,et al.  Current status of prognostic profiling in breast cancer. , 2008, The oncologist.

[57]  J. Sirvent,et al.  Prognostic value of apoptosis in breast cancer (pT1-pT2). A TUNEL, p53, bcl-2, bag-1 and Bax immunohistochemical study. , 2004, Histology and histopathology.

[58]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[59]  D. Dabbs,et al.  Luminal B breast tumors are not HER2 positive , 2008, Breast Cancer Research.

[60]  G. Colditz,et al.  Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer , 2008, Breast Cancer Research.

[61]  M. Dowsett,et al.  Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  S. Kesari,et al.  Breast cancer surface receptors predict risk for developing brain metastasis and subsequent prognosis , 2008, Breast Cancer Research.

[63]  S. Ménard,et al.  Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  C Caldas,et al.  Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. , 2008, Breast.

[65]  D. Larsimont,et al.  Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel , 2008, Clinical Cancer Research.

[66]  Max S Wicha,et al.  Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Jerry Younger,et al.  VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy , 2008, Clinical Cancer Research.

[68]  A. Rim,et al.  Trends in breast cancer screening and diagnosis. , 2008, Cleveland Clinic journal of medicine.

[69]  A. Glas,et al.  The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study , 2009, Breast Cancer Research and Treatment.

[70]  Passeig Vall d'Hebron Targeted therapies in breast cancer: Where are we now? , 2008 .

[71]  V. Heinemann,et al.  Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. , 2008, The oncologist.

[72]  G. Giles,et al.  Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). , 1999, Journal of the National Cancer Institute. Monographs.

[73]  J. Henson,et al.  Survival in patients with brain metastases from breast cancer , 2008, Cancer.

[74]  H. Uno,et al.  Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer , 2008, Journal of Cancer Research and Clinical Oncology.

[75]  G. Botti,et al.  Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. , 2008, Clinical breast cancer.

[76]  Barbara McGrogan,et al.  Taxanes, microtubules and chemoresistant breast cancer. , 2008, Biochimica et biophysica acta.

[77]  J. Foekens,et al.  DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and , 2007, European journal of cancer.

[78]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[79]  C. Nguyen,et al.  A candidate molecular signature associated with tamoxifen failure in primary breast cancer , 2008, Breast Cancer Research.

[80]  D. Plewes,et al.  Systematic Review: Using Magnetic Resonance Imaging to Screen Women at High Risk for Breast Cancer , 2008, Annals of Internal Medicine.

[81]  Jill M Kolesar,et al.  Gene-expression assays: new tools to individualize treatment of early-stage breast cancer. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[82]  L. Pusztai,et al.  Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[83]  H. McArthur An overview of HER-targeted therapy with lapatinib in breast cancer , 2009, Advances in therapy.

[84]  M. Piccart-Gebhart,et al.  HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? , 2008, Anti-cancer agents in medicinal chemistry.

[85]  S. Küçücük,et al.  Lower Level of MAPK Expression Is Associated with Anthracycline Resistance and Decreased Survival in Patients with Hormone Receptor Negative Breast Cancer , 2008, Cancer investigation.

[86]  T. Curran,et al.  FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA , 1982, Journal of virology.

[87]  J. Meza,et al.  The molecular etiology of breast cancer: Evidence from biomarkers of risk , 2007, International journal of cancer.

[88]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[89]  S Gori,et al.  Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[90]  M. Cristofanilli,et al.  Integrating Circulating Tumor Cell Assays into the Management of Breast Cancer , 2007, Current treatment options in oncology.

[91]  D. Ross,et al.  Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials , 2008, Clinical Cancer Research.

[92]  D. Mavroudis,et al.  Circulating tumor cells in breast cancer , 2008, Current opinion in obstetrics & gynecology.

[93]  S. Fox,et al.  Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  M. Daidone,et al.  Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. , 1999, Endocrine-related cancer.

[95]  D. Hicks,et al.  Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. , 2009, Archives of pathology & laboratory medicine.

[96]  A. D. Van den Abbeele,et al.  Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  A. Harris,et al.  Targeting tumour hypoxia in breast cancer. , 2008, European journal of cancer.

[98]  L. Mariani,et al.  Serial determination of CEA and CA 15.3 in breast cancer follow-up: An assessment of their diagnostic accuracy for the detection of tumour recurrences , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[99]  J. Baak,et al.  Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[100]  A. Hamburger The Role of ErbB3 and its Binding Partners in Breast Cancer Progression and Resistance to Hormone and Tyrosine Kinase Directed Therapies , 2008, Journal of Mammary Gland Biology and Neoplasia.

[101]  Charles M. Perou,et al.  Triple-Negative Breast Cancer: Risk Factors to Potential Targets , 2008, Clinical Cancer Research.

[102]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[103]  R. Gelber,et al.  Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  J. Baselga,et al.  The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 , 2008, Nature Clinical Practice Oncology.

[105]  F. Esteva,et al.  Serum HER‐2/neu and relative resistance to trastuzumab‐based therapy in patients with metastatic breast cancer , 2008, Cancer.

[106]  M. Ellis,et al.  Can Molecular Markers Predict When to Implement Treatment With Aromatase Inhibitors in Invasive Breast Cancer , 2006 .

[107]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[108]  N. Saijo,et al.  A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer , 2009, International Journal of Clinical Oncology.

[109]  H. Mouridsen,et al.  The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D , 2008, Acta oncologica.

[110]  I. Ellis,et al.  Impact of Basal-Like Breast Carcinoma Determination for a More Specific Therapy , 2008, Pathobiology.